Endonovo Therapeutics (OTCMKTS:ENDV) versus GigCapital5 (NYSE:GIA) Critical Analysis

GigCapital5 (NYSE:GIA) and Endonovo Therapeutics (OTCMKTS:ENDV) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for GigCapital5 and Endonovo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GigCapital5	0	0	0	0	N/A
Endonovo Therapeutics	0	0	0	0	N/A

Volatility and Risk

GigCapital5 has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500.

Valuation and Earnings

This table compares GigCapital5 and Endonovo Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GigCapital5	N/A	N/A	-$2.77 million	N/A	N/A
Endonovo Therapeutics	$140,000.00	2.55	$6.93 million	N/A	N/A

Endonovo Therapeutics has higher revenue and earnings than GigCapital5.

Profitability

This table compares GigCapital5 and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GigCapital5	N/A	N/A	-14.85%
Endonovo Therapeutics	4,911.97%	-29.58%	755.18%

Institutional and Insider Ownership

27.3% of GigCapital5 shares are owned by institutional investors. 75.4% of GigCapital5 shares are owned by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

About GigCapital5

GigCapital5, Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Palo Alto, California.GigCapital5, Inc operates as a subsidiary of GigAcquisitions5, LLC

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.